Jazz Pharmaceuticals PLC’s shares advanced to a record $265.54 on Tuesday, extending a rally that has pushed the stock up 109.94% over the past 12 months.
The biopharmaceutical company reported second-quarter revenue of $1.21 billion, exceeding the consensus estimate of $1.11 billion, while earnings per share came in at $5.71, below the expected $6.18. The EPS shortfall was attributed to dilution from convertible debt and ongoing research and development spending, according to company filings.
Jazz Pharmaceuticals, which trades at a price-to-earnings ratio of 17.68, maintains gross profit margins of 91%, underscoring its strong profitability in its core markets. The company’s market capitalization stands at $17.09 billion, reflecting its expanded valuation amid the stock’s surge.
Analysts have responded with upward revisions to price targets. Stifel raised its target to $275, Truist Securities lifted its forecast to $264, TD Cowen set a new target at $300, and Piper Sandler increased its projection to $310. Data from InvestingPro indicates that 11 analysts have revised earnings estimates upward for the upcoming period, while the platform’s fair-value models—using 17 valuation methodologies—suggest the company remains undervalued.
The company’s portfolio includes Xywav, Epidiolex, and Zepzelca, with revenue performance driven by strong demand in its neurology and oncology segments. The stock’s ascent follows broader gains in the biotech sector, where companies with robust pipeline visibility and near-term revenue visibility have attracted investor interest.
InvestingPro, which tracks analyst revisions and valuation metrics, also highlights 13 exclusive tips for subscribers as part of its analytical framework.
